K-numberK260007
Device nameHyaluronic Acid Vaginal Suppository (HA 5 mg); Hyaluronic Acid Vaginal Suppository (HA 10 mg)
ApplicantHudi Pharma Srl
Product codeNUC
Device classClass II
Decision dateApr 1, 2026
DecisionSubstantially Equivalent
Regulation884.5300
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

The Hyaluronic Acid Vaginal Suppository (HA 5 mg and HA 10 mg) is an over-the-counter vaginal lubricant designed to moisturize and lubricate the vagina, enhance comfort and ease during intimate sexual activity, and supplement the body's natural lubrication. The device is a solid suppository (1.8 g each) that dissolves in the vaginal cavity due to body temperature, releasing hyaluronic acid sodium salt to create a moist environment. The product is not compatible with condoms.

Technological characteristics

The subject device contains hyaluronic acid sodium salt, vitamin E, cocoa butter, and semi-synthetic glycerides in a glyceride base, compared to the predicate's hyaluronic acid, glycerides, and sweet almond oil. Both are non-sterile vaginal suppositories in PVC/PE blister packaging. The subject device offers 5 mg or 10 mg HA content with a 1-year shelf life, versus the predicate's 10 mg HA with 24 months shelf life. Microbial limits are identical (aerobic microbial count <100 cfu/g, mold/yeast <10 cfu/g), and both are absent of pathogenic organisms.

Test standards cited

Biocompatibility testing was performed per ISO 10993-1:2018 and the 2023 FDA guidance, including cytotoxicity (ISO 10993-5:2009), vaginal irritation (ISO 10993-23:2021), skin sensitization (ISO 10993-10:2021), and acute systemic toxicity (ISO 10993-11:2017). Shelf life and stability were evaluated via real-time aging studies.

Substantial equivalence argument

The subject device is substantially equivalent to the predicate (Revaree plus vaginal suppositories, K213220) because both share the same intended use—vaginal lubrication during intimate sexual activity—and the same over-the-counter status and delivery mechanism. Although formulation ingredients and shelf life differ, these differences do not raise different questions of safety or effectiveness. Biocompatibility testing confirmed the subject device is non-cytotoxic, non-irritating, non-sensitizing, and not systemically toxic, demonstrating safety and effectiveness equivalent to the predicate.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →